Amarin Corp Plc (AMRN)

[HDGabor]

Hi Kiwi,

The AMRN vs AZN / Omthera case is about 662 patent.
The 662 patent: which requires that treatment with claimed formulation not increase LDL-C by more than 20%

AZN's noninfringement argument is that Epanova had an LDL-C increase of greater than 21%(2g) and 26%(4g) relative to baseline within Epanova arm.

However the patent is "against a baseline or a placebo arm".

Epanova had an LDL-C increase of 13%(2g) and 15%(4g) relative to placebo arm within Epanova study.

The case / claim not related to Marine, to Anchor or to statin.